Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 1 (2017) THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES Abstract  similar documents
N. Z. Musina, V. K. Fedyaeva
"... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... with the Oswestry low back pain disability questionnaire, converted into utilities and transformed into quality ..."
 
Vol 6, No 3 (2013) METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES Abstract  similar documents
R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze
"... Utility assessment is one of the most important stages of pharmacoeconomic analysis. Most ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... and effectiveness in terms of QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combination ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... -effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..."
 
Vol 5, No 2 (2012) METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES Abstract  similar documents
R. I. Yagudina, I. V. Sorokovikov
"... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... полного цитогенетического ответа (ПЦО) на протяжении одного года из расчета на одного пациента с ХФ ХМЛ ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS Abstract  similar documents
M. V. Protsenko
"... of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost ..."
 
Vol 7, No 2 (2014) CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM Abstract  similar documents
I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek
"... -effectiveness” and “cost-utility” analyses have been used. The target population of patients suffering from ..."
 
Vol 11, No 4 (2018) International experience in determining the cost-effectiveness thresholds Abstract  similar documents
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
"... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..."
 
Vol 12, No 3 (2019) Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics Abstract  PDF (Eng)  similar documents
S. V. Ponomarenko
 
Vol 12, No 3 (2019) Approaches to assessing the demand for medical personnel in the Russian Federation Abstract  similar documents
S. N. Tishkina , T. G. Alkhasov , D. V. Lukyantseva , T. P. Bezdenezhnykh 
"... которых относятся расчет потребности во врачебных кадрах и мероприятия по привлечению кадров (целевые ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... + alloSCT vs Ch ± RT per life year (LY) and quality-adjusted life year (QALY) was calculated. In the second ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION Abstract  similar documents
V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina
"... (QALY) is growing, which makes it advisable to use ART in health care on larger scale. ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... pharmacoeconomic analyses: «cost – effectiveness,» «cost – utility» and « budget impact». Analysis included ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... (QALYs), adverse events, and other clinical outcomes. The search for the relevant information ..."
 
Vol 6, No 1 (2013) THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION Abstract  similar documents
A. Yu. Kulikov, Yu. L. Akimova
"... вакцинопрофилактики. Приведены критерии выбора показателей эффективности для различных типов вакцин, расчеты затрат на ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... анализ «затраты-полезность» в соответствии с рекомендациями Рабочей группы по оценке затратной ..."
 
Vol 10, No 4 (2017) THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE Abstract  similar documents
Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva
"... . Структура стандарта обеспечивает возможность расчета затрат на реализацию ПГГ, однако опыт работы над ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... в статье представлены результаты расчета необходимых финансовых затрат на лекарственное ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... церебролизина для лечения ОНМК по ишемическому типу позволяет сэкономить примерно 1,47 млрд руб. в год в расчете ..."
 
Vol 8, No 4 (2015) HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS Abstract  similar documents
N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova
"... влияния внешних факторов; 3) расчет скорректированной оценки эффективности без учета влияния внешних ..."
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID Abstract  similar documents
K. V. Danilova, I. M. Razdorskaya
"... концептуальный подход, включающий анализ производственного признака, стоимостной анализ, методика расчета ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... (если необходимо)) и проведением процедуры Мараскуило. Расчеты выполнены в Microsoft Excel (прикладные ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... анализ влияния на бюджет. Расчеты проводились в модели, построенной в Microsoft Excel. В анализе «затраты ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... . Материалы и методы. Выполнен анализ влияния на бюджет (АВБ) и анализ «затраты-эффективность». Расчеты ..."
 
Vol 12, No 3 (2019) Overview of the existing opportunities and limitations of the state guarantees program for provision of free medical care to citizens Abstract  similar documents
D. V. Fedyaev , R. V. Gostishchev , V. A. Lemeshko , O. I. Ivakhnenko 
"... гарантий применяются ограниченно. Расчет подушевого норматива финансирования субъекта РФ зависит только от ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
A. U. Kulikov, I. A. Komarov
"... «влияния на бюджет» и расчета показателя «упущенных возможностей». ..."
 
Vol 7, No 3 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA Abstract  similar documents
A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova
"... расчет прямых медицинских, прямых немедицинских и косвенных затрат. Применялись три торговых наименования ..."
 
Vol 7, No 4 (2014) MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES Abstract  similar documents
M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya
"... древо решений и модель Маркова мы применили для проведения расчета ожидаемых затрат при сравнении ..."
 
Vol 8, No 2 (2015) CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER Abstract  similar documents
Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov
"... имплантируемых венозных порт-систем у 2262 детей в возрасте от 2 мес. до 17 лет. Для расчетов затрат были взяты ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... болезни, включающий расчет прямых медицинских затрат на медицинские услуги, лекарственные препараты ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... , что расходы на один месяц лечения регорафенибом в расчете на одного пациента составляют около 255 тыс ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... жидкой искусственной смеси вместо сухой. Выполнен анализ чувствительности результатов расчетов к ..."
 
Vol 12, No 3 (2019) Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” Abstract  similar documents
S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva 
"... Geriatrics) и критерия Чарлсона. В расчете «стоимости болезни» учитывали только прямые затраты. Результаты ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS Abstract  similar documents
O. Yu. Korennova, L. V. Shukil', S. N. Mal'tsev, I. A. Klinyshkov, N. M. Leganova, E. A. Turusheva, T. V. Kropotina
"... круглосуточного и дневного стационаров. Материалы и методы. В основу фармакоэкономических расчетов по методу ..."
 
Vol 9, No 3 (2016) HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE Abstract  similar documents
A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
"... фармакоэкономический анализ с расчетом прямых затрат и анализом эффективности затрат. Критерием эффективности терапии ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... ингибиторов ФНО-α. Материалы и методы. Для расчетов использованы статистические данные, литературные ..."
 
Vol 10, No 4 (2017) EVALUATING THE USE OF HOSPITAL BED CAPACITY IN MEDICAL ORGANIZATIONS Abstract  similar documents
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali, M. A. Voinov, V. V. Omel’yanovskii
"... фонда в статье произведены расчеты и сравнения результатов по основным показателям эффективности ..."
 
Vol 11, No 4 (2018) Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach Abstract  similar documents
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya
"... метода экстраполяции. Анализ затрат включает расчет стоимости рассматриваемых лекарственных препаратов ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... результатов исследования к колебаниям значений исходных параметров. Результаты расчетов наиболее чувствительны ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic study of nutrition support in the conditions of current health care system in Russia Abstract  similar documents
I. A. Metelkin, R. I. Yagudina
"... : при проведении фармакоэкономического исследования все расчеты производились для трех групп пациентов в ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... во всех регионах России. Исследование проводилось в период с сентября по декабрь 2015 г. Для расчетов ..."
 
Vol 10, No 2 (2017) PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY Abstract  similar documents
A. V. Rudakova, S. A. Protsenko, I. A. Koroleva
"... базовом варианте расчет осуществляли для пациента с массой тела 70 кг. Предполагали, что ниволумаб ..."
 
1 - 50 of 56 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)